+325.3%
STX vs MRNA
+485.7%
-160.4%
-31.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.7% | +5.4% | -9.1% | -3.6% |
| 7D | -2.3% | -1.1% | -1.2% | -2.3% |
| 30D | -5.5% | +126.1% | -131.6% | -2.1% |
| 3M | -4.3% | +190.0% | -194.3% | -8.6% |
| 6M | +115.6% | +157.2% | -41.6% | +111.1% |
| YTD | +202.2% | +388.2% | -186.0% | +146.5% |
| 1Y | +325.3% | +467.0% | -141.7% | +226.1% |
| All | +325.3% | +485.7% | -160.4% | +226.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling